Dexamfetamine modified release

Drug Profile

Dexamfetamine modified release

Latest Information Update: 04 Nov 2013

Price : $50

At a glance

  • Originator Ironshore Pharmaceutical and Development
  • Class Amphetamines
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Attention-deficit hyperactivity disorder

Most Recent Events

  • 30 Sep 2013 Ironshore Pharmaceutical and Development completes a phase I/II trial in Attention-deficit hyperactivity disorder in Canada (NCT01886469)
  • 12 Jul 2013 Phase-I/II clinical trials in Attention-deficit hyperactivity disorder in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top